Racial and Ethnic Disparities and Health Inequity in Lung CancerPremiere Date: Wednesday, October 12, 2022
This activity offers CE credit for:%>
- Certified Case Managers (CCMC)
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, October 12, 2025
|Ana I. Velázquez Mañana, MD, MSc (Moderator)
Assistant Professor, Division of Hematology Oncology
Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
|Gilberto de Lima Lopes Junior, MD, MBA, FASCO
Professor of Clinical Medicine
Interim Chief, Division of Medical Oncology
Miller School of Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Sylvester Comprehensive Cancer
University of Miami Health Systems
Every two and a half minutes, someone receives a diagnosis of lung cancer in the United States. Each day, nearly 400 people succumb to lung cancer. While the survival rate for lung cancer—the leading cause of cancer mortality—has markedly increased over the past 5 years, gaps in early diagnosis, treatment options and access, survival rate, and more remain for underserved populations, including those of varying racial and ethnic groups. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis, clinical management and treatment, prognosis, and survival rate.
In this CME Outfitters podcast, expert faculty will review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for underserved racial and ethnic underserved patients with lung cancer. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve lung cancer treatment.
At the end of this CE activity, participants should be able to:
- Understand and acknowledge the influence of bias, disparities, and inequities on lung cancer care.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, PAs, nurse practitioners, nurses, pharmacists, dietitians, and case managers specializing in oncology, pathology, radiology, pulmonology, and/or primary care.
CCMC Credit (Certified Case Managers):
This program has been approved for .75 hours by the Commission for Case Manager Certification (CCMC).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning formats: Enduring material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.75 contact hours
Dr. Velázquez Mañana reports the following financial relationships:
Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.
Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology
Dr. Lopes reports the following financial relationships:
Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Abbvie Inc.; Adaptimmune Therapeutics plc.; AstraZeneca; Bavarian Nordic; Blueprint Medicines Corporation; Bristol Myers Squibb Company; EMD Serono, Inc.; E.R. Squibb & Sons, LLC; G1 Therapeutics, Inc.; Genentech, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Lilly; Lucence Diagnostics; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Rgenix, Inc.; Roche; Tesaro, Inc.; and Xilis, Inc.
Stock Options: Lucence Diagnostics and Xilis, Inc.
Travel, Accommodations, or Expenses: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; E.R. Squibb & Sons, LLC; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; Pharmacyclics, Inc.; Seagen Inc.; and Seattle Genetics, Inc.
Other Material or Financial Support: : Mirati Therapeutics, Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).